Company Overview

Olema Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing targeted therapies for women’s cancers, particularly estrogen receptor (ER)-positive breast cancer. The company operates within the biotechnology and oncology sectors and concentrates on endocrine-driven cancers where resistance to standard hormonal therapies remains a significant clinical challenge. Olema’s primary value driver is its pipeline of selective estrogen receptor antagonists and related precision oncology programs designed to improve outcomes for patients with hormone receptor-positive malignancies.

The company’s lead product candidate is palazestrant (OP-1250), an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader (SERD) being evaluated in advanced and metastatic breast cancer settings. Olema was founded in 2006 and later became publicly traded on Nasdaq under the ticker OLMA following its initial public offering in 2020. Since its founding, the company has evolved from a discovery-stage oncology platform into a clinical-stage developer with an emphasis on combination therapies, biomarker-driven treatment approaches, and next-generation endocrine therapies intended to address resistance mechanisms associated with current standards of care.

Business Operations

Olema primarily operates through a single biotechnology research and development platform focused on oncology therapeutics. Its operations are centered on advancing proprietary drug candidates through preclinical development, clinical trials, regulatory engagement, and strategic collaborations. The company does not currently generate commercial product revenue and instead relies primarily on capital raised through equity offerings, public market financing, and prior collaboration-related funding. Its principal operational activities include clinical development, translational science, regulatory affairs, and intellectual property management.

The company’s core asset portfolio includes palazestrant (OP-1250) and earlier-stage discovery programs targeting hormone receptor biology and tumor signaling pathways. Olema maintains internal capabilities in medicinal chemistry, translational oncology research, and biomarker development. Operations are primarily U.S.-based, with clinical trial activity extending internationally through investigator sites and contract research organizations. The company has historically engaged with academic institutions, clinical investigators, and external manufacturing partners to support development and trial execution. Public disclosures identify strategic relationships with clinical research networks and manufacturing service providers rather than large-scale commercial joint ventures or majority-owned operating subsidiaries.

Strategic Position & Investments

Olema’s strategic direction is centered on becoming a differentiated developer of endocrine therapies for breast cancer, particularly in settings where resistance to existing ER-targeted therapies limits effectiveness. The company has emphasized development of therapies that may demonstrate improved efficacy, central nervous system penetration, and combinability with other oncology agents. Current growth initiatives include expanding clinical evaluation of palazestrant across monotherapy and combination regimens, including studies involving CDK4/6 inhibitors and other targeted therapies commonly used in metastatic breast cancer treatment.

The company continues to invest heavily in research and development infrastructure, clinical trial expansion, and pipeline diversification. Olema has publicly highlighted biomarker-guided development and precision medicine approaches as part of its long-term strategy. In addition to its lead program, the company has disclosed ongoing discovery efforts targeting nuclear receptor biology and endocrine resistance pathways. Available public filings and investor materials do not indicate major completed acquisitions or broad portfolio ownership structures comparable to large pharmaceutical companies. Data regarding significant acquisition activity is inconclusive based on available public sources.

Geographic Footprint

Olema is headquartered in San Francisco, California, and its primary corporate and research activities are concentrated within the United States. The company’s operational footprint includes clinical trial sites and development partnerships across multiple geographic regions supporting oncology studies in advanced breast cancer populations. While it remains principally U.S.-focused, its clinical programs involve patients, investigators, and research organizations in selected international markets.

The company’s market and development relevance is most closely tied to the global oncology therapeutics industry, particularly the treatment market for hormone receptor-positive breast cancer across North America, Europe, and parts of the Asia-Pacific region. Olema’s international influence currently stems from clinical development activities and potential future commercialization opportunities rather than large-scale foreign operating subsidiaries or manufacturing networks.

Leadership & Governance

Olema was founded by oncology scientist Dr. Sean Bohen, who previously served in executive leadership roles within the biotechnology industry and helped shape the company’s scientific and clinical development strategy. The company’s leadership has consistently emphasized science-driven oncology innovation, disciplined clinical execution, and development of differentiated endocrine therapies for underserved patient populations.

Key executives and leaders include:

• Sean Bohen, M.D., Ph.D. – President, Chief Executive Officer, and Chair
• Yvonne Greer – Chief Financial Officer
• Todd Baumgartner, M.D. – Chief Medical Officer
• Adrian Senderowicz, M.D. – Senior Vice President, Clinical Development
• Michael Evans, Ph.D. – Senior Vice President, Research

The company’s governance structure includes a board of directors composed of biotechnology executives, scientific leaders, and financial professionals with experience in oncology drug development, public company governance, and pharmaceutical commercialization. Leadership communications in public filings and investor presentations emphasize disciplined capital allocation, clinical data generation, and long-term value creation through differentiated oncology therapeutics.